Explore /
Poster
/ A retrospective analysis of post second-line chemotherapy treatment outcomes for patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions.

A retrospective analysis of post second-line chemotherapy treatment outcomes for patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions.

Authors

Milind M. Javle

MD Anderson Cancer Center, Houston, TX

Milind M. Javle , Saeed Sadeghi , Anthony B. El-Khoueiry , Lipika Goyal , Philip Agop Philip , Robin Kate Kelley , Ivan Borbath , Teresa Macarulla , Wei-Peng Yong , Suebpong Tanasanvimon , Amit Pande , Gary Li , Michael Howland , Craig Berman , Ghassan K. Abou-Alfa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT02150967

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4591)

DOI

10.1200/JCO.2020.38.15_suppl.4591

Abstract #

4591

Poster Bd #

199

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Gastrointestinal Cancers Symposium

$First-308: Phase III study of tinengotinib versus physician's choice in patients with FGFR-altered, chemotherapy- and FGFR inhibitor–refractory/relapsed cholangiocarcinoma.$